<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1016/j.joca.2022.02.104</dc:identifier><dc:language>eng</dc:language><dc:creator>Remírez de Ganuza, C.</dc:creator><dc:creator>Paesa, M.</dc:creator><dc:creator>García-Álvarez, F.</dc:creator><dc:creator>Rodríguez-Yoldi, M.</dc:creator><dc:creator>Irusta, S.</dc:creator><dc:creator>Arruebo, M.</dc:creator><dc:creator>Mendoza, G.</dc:creator><dc:title>Ipriflavone-loaded poly(d,l-lactide-co-glycolide) acid nanoparticles for the treatment of osteoarthritis</dc:title><dc:identifier>ART-2022-141302</dc:identifier><dc:description>Purpose: Osteoarthritis (OA) is a degenerative disease that affects the entire joint and is characterized by the destruction of cartilage, alterations in the structure of the subchondral bone and chronic inflammation of the synovial membrane, which entails pain and joint stiffness, and therefore the deterioration of the patient's quality of life...</dc:description><dc:date>2022</dc:date><dc:source>http://zaguan.unizar.es/record/147968</dc:source><dc:doi>10.1016/j.joca.2022.02.104</dc:doi><dc:identifier>http://zaguan.unizar.es/record/147968</dc:identifier><dc:identifier>oai:zaguan.unizar.es:147968</dc:identifier><dc:identifier.citation>Osteoarthritis and cartilage 30, Suppl. 1 (2022), S84-S85</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>